Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,889 | 422 | 2,423 |
| Samples | 424 | 85 | 332 |
| Peptides | 318 | 49 | 282 |
Function
PPP2R2B · Protein phosphatase 2 regulatory subunit Bbeta
The product of this gene belongs to the phosphatase 2 regulatory subunit B family. Protein phosphatase 2 is one of the four major Ser/Thr phosphatases, and it is implicated in the negative control of cell growth and division. It consists of a common heteromeric core enzyme, which is composed of a catalytic subunit and a constant regulatory subunit, that associates with a variety of regulatory subunits. The B regulatory subunit might modulate substrate selectivity and catalytic activity. This gene encodes a beta isoform of the regulatory subunit B55 subfamily. Defects in this gene cause autosomal dominant spinocerebellar ataxia 12 (SCA12), a disease caused by degeneration of the cerebellum, sometimes involving the brainstem and spinal cord, and in resulting in poor coordination of speech and body movements. Multiple alternatively spliced variants, which encode different isoforms, have been identified for this gene. The 5' UTR of some of these variants includes a CAG trinucleotide repeat sequence (7-28 copies) that can be expanded to 55-78 copies in cases of SCA12. [provided by RefSeq, Jul 2016].
Isoforms & Proteins
8 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 239 amino-acid changes on canonical ENST00000394411 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PPP2R2B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PPP2R2B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Melanoma | 7/210 3% | 59/1899 3% |
| Endometrial Carcinoma | 1/42 2% | 19/612 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Colorectal Carcinoma | 12/143 8% | 65/3239 2% |
| Non-Small Cell Lung Carcinoma | 12/304 4% | 17/1390 1% |
| Other Solid Cancers | 1/94 1% | 25/1515 2% |
| Rhabdomyosarcoma | 3/33 9% | 0/171 0% |
| Gastric Carcinoma | 2/74 3% | 24/1809 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 8/810 1% |
| Ovarian Carcinoma | 7/109 6% | 4/998 0% |
| Bladder Carcinoma | 2/58 3% | 8/956 1% |
| Neuroendocrine Tumour | 4/154 3% | 3/577 1% |
| Osteosarcoma | 0/45 0% | 2/166 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Esophageal Carcinoma | 2/23 9% | 5/769 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Non-Cancerous | 1/104 1% | 6/830 1% |
| Prostate Carcinoma | 2/13 15% | 12/2105 1% |
| Other Sarcomas | 3/69 4% | 2/699 0% |
| Biliary Tract Carcinoma | 1/54 2% | 5/950 1% |
| Head and Neck Carcinoma | 3/85 4% | 6/1574 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 11/2550 0% |
| Pancreatic Carcinoma | 2/89 2% | 5/1611 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Glioma | 1/52 2% | 7/2127 0% |
Mutation Distribution
Where PPP2R2B is mutated · all tissues, split by cell line vs tissue
How many mutations in PPP2R2B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,889 mutations in PPP2R2B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|